Revolution Medicines(US:RVMD) Globenewswire·2025-10-29 20:05Core Insights - Revolution Medicines, Inc. is set to report its financial results for Q3 2025 on November 5, 2025, after market close [1] - A webcast will be hosted by the senior management team at 4:30 p.m. ET to discuss the financial results and corporate progress [1] Company Overview - Revolution Medicines is a late-stage clinical oncology company focused on developing targeted therapies for RAS-addicted cancers [3] - The company's R&D pipeline includes RAS(ON) inhibitors such as daraxonrasib (RMC-6236), elironrasib (RMC-6291), and zoldonrasib (RMC-9805), which are currently in clinical development [3] - The company plans to advance RMC-5127, a RAS(ON) G12V-selective inhibitor, into clinical development next [3] - Additional pipeline opportunities include RAS(ON) mutant-selective inhibitors like RMC-0708 (Q61H) and RMC-8839 (G13C) [3]